ARTICLE | Emerging Company Profile
Duke Street: IOmet alumni reunite for cancer company sequel
Start-up aims to take its small molecule DNA damage repair and immunotherapy assets into the clinic
August 10, 2022 12:42 AM UTC
Six years after its management team’s last biopharma was acquired, Duke Street Bio emerged from stealth in May with a small molecule PARP program and an immunotherapy approach that targets cancer cells rather than T cells.
That last biopharma was IOmet Pharma Ltd., which was led by CEO Alan Wise and co-founded by Peter Trill and Barry McGuinness. IOmet was developing small molecule inhibitors of IDO and TDO until 2016, when Merck & Co. Inc. (NYSE:MRK) acquired it for $400 million...